Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NEULAND LABS ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NEULAND LABS Mar-23 |
ADCOCK INGRAM Jun-14 |
NEULAND LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,004 | 319 | - | |
Low | Rs | 966 | 230 | - | |
Sales per share (Unadj.) | Rs | 928.4 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 127.4 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 168.6 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
Avg Dividend yield | % | 0.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 774.8 | 74.5 | - | |
Shares outstanding (eoy) | m | 12.83 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.6 | 2.9 | 55.3% | |
Avg P/E ratio | x | 11.7 | -11.5 | -101.5% | |
P/CF ratio (eoy) | x | 8.8 | -13.9 | -63.6% | |
Price / Book Value ratio | x | 1.9 | 3.7 | 52.0% | |
Dividend payout | % | 7.8 | 0 | - | |
Avg Mkt Cap | Rs m | 19,052 | 46,340 | 41.1% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 2,018 | 2,908 | 69.4% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,912 | 16,016 | 74.4% | |
Other income | Rs m | 97 | 112 | 86.9% | |
Total revenues | Rs m | 12,009 | 16,128 | 74.5% | |
Gross profit | Rs m | 2,718 | -2,775 | -97.9% | |
Depreciation | Rs m | 528 | 691 | 76.4% | |
Interest | Rs m | 131 | 434 | 30.1% | |
Profit before tax | Rs m | 2,157 | -3,788 | -56.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 522 | 237 | 220.6% | |
Profit after tax | Rs m | 1,635 | -4,036 | -40.5% | |
Gross profit margin | % | 22.8 | -17.3 | -131.7% | |
Effective tax rate | % | 24.2 | -6.2 | -387.4% | |
Net profit margin | % | 13.7 | -25.2 | -54.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,609 | 11,730 | 64.9% | |
Current liabilities | Rs m | 4,390 | 6,600 | 66.5% | |
Net working cap to sales | % | 27.0 | 32.0 | 84.4% | |
Current ratio | x | 1.7 | 1.8 | 97.5% | |
Inventory Days | Days | 6 | 111 | 5.7% | |
Debtors Days | Days | 1,109 | 124 | 894.4% | |
Net fixed assets | Rs m | 8,189 | 6,838 | 119.8% | |
Share capital | Rs m | 129 | 74 | 173.5% | |
Net worth | Rs m | 9,941 | 12,571 | 79.1% | |
Long term debt | Rs m | 742 | 4,418 | 16.8% | |
Total assets | Rs m | 15,798 | 23,747 | 66.5% | |
Interest coverage | x | 17.5 | -7.7 | -226.5% | |
Debt to equity ratio | x | 0.1 | 0.4 | 21.3% | |
Sales to assets ratio | x | 0.8 | 0.7 | 111.8% | |
Return on assets | % | 11.2 | -15.2 | -73.7% | |
Return on equity | % | 16.4 | -32.1 | -51.2% | |
Return on capital | % | 21.4 | -19.8 | -108.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,372 | 1,367 | 173.5% | |
From Investments | Rs m | -615 | -420 | 146.5% | |
From Financial Activity | Rs m | -1,358 | 4,009 | -33.9% | |
Net Cashflow | Rs m | 403 | 4,957 | 8.1% |
Compare NEULAND LABS With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare NEULAND LABS With: ANUH PHARMA UNICHEM LAB ROOPA INDUSTRIES ZANDU REALTY BROOKS LAB
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.